Pure Global
NCT04617080

Safety and Efficacy of Different Add Powers With a New Presbyopic Lasik Treatment Algorithm

Prospective Clinical Study to Evaluate the Safety and Efficacy of Different Add Powers With a New Presbyopic Lasik Treatment Algorithm
Bausch & Lomb Incorporated·ClinicalTrials.gov·procedureRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Ametropia
Drug/Device/Intervention
SUPRACOR Regular
Study type
Interventional
Intervention type
procedure
Sponsor & location
Primary sponsor
Bausch & Lomb Incorporated
Location
Makati City, Philippines
Timeline & enrollment
Phase
N/A
Start date
Jan 26, 2021
End date
Nov 01, 2022
Enrollment
60 participants
Primary outcome

Binocular Uncorrected Distance Visual Acuity (UDVA)

Summary

This is a prospective, comparative, randomized, controlled, open-label, single-surgeon,
 single-center PMCF clinical study whereby presbyopic patients undergoing refractive surgery
 will receive a SUPRACOR treatment for the correction in the non-dominant eye and a PROSCAN
 refractive treatment in the dominant eye to correct for ametropia.
 
 The participants will be randomized to either a SUPRACOR regular (100%) or SUPRACOR strong
 (130%) treatment with a 1:1 ratio.

ICD-10 classifications
Amblyopia ex anopsiaAmoebiasisAmoebiasis, unspecifiedMyoclonusOesophagitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04617080
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04617080 through Pure Global AI's free database. This phase not specified trial is sponsored by Bausch & Lomb Incorporated and is currently Recruiting. The study focuses on Ametropia. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.